@article{8f956d10a5654ef9b7e5ad6ebc4444a8,
title = "Reply to “Guarantee-time bias in studies on the relationship between immune-related adverse events and antitumor activity”",
author = "Foster, \{Corey C.\} and Seiwert, \{Tanguy Y.\}",
note = "Funding Information: Tanguy Y. Seiwert reports clinical trial funding from BMS, Genentech/Roche, Merck/MSD, Nanobiotix, AstraZeneca, Cue Biopharma, Regeneron, and Innate Pharma; participation on advisory boards for Innate Pharma, Merck/MSD, Nanobiotix, Cue Biopharma, Vir Biotechnology, Coherus, and Sanofi; honoraria from Merck/MSD; and participation on steering committees for BioNTech and AstraZeneca. The other author made no disclosures.",
year = "2022",
month = jul,
day = "1",
doi = "10.1002/cncr.34242",
language = "English (US)",
volume = "128",
pages = "2551--2552",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "13",
}